Company logo

Legal Counsel

Unlock Employer

Posted Jun 9, 2026

Remote · US · UK · Norway Full Time
Est. $110K – $150K/yr

Overview

An international coalition focused on epidemic and pandemic preparedness is seeking a Legal Counsel for a fixed term of 12 months, with a start date expected in July or August. The organization aims to accelerate vaccine development against emerging infectious diseases and ensure equitable access globally.

Responsibilities

  • Report directly to the Head of Legal, Business Transactions and Access.
  • Serve as lead lawyer for selected projects in formation and implementation phases, including grants and investments in vaccine candidates and platform technologies.
  • Support sustainable laboratory and manufacturing networks, clinical trial networks, and pharmacovigilance for vaccine candidates.
  • Provide legal advice on collaborations across vaccine and biologics R&D, manufacturing, supply chain, and commercialization.
  • Translate commercial terms into contractual commitments, focusing on drafting and negotiating access and commercialization terms in funding agreements.
  • Advise on the application of organizational policies and procedures.
  • Create and maintain legal and agreement templates, including automation where needed.
  • Manage external counsel and internal subject matter experts as required.
  • Engage externally with senior stakeholders, legal, commercial, and operations teams, representing the organization in industry or sector bodies as needed.
  • Actively contribute to the legal team and support division tasks and ad hoc responsibilities.

Requirements

  • 3-7 years post-qualification experience, preferably from a major law firm or as in-house counsel.
  • Experience in transactional work is necessary; industry experience in pharma or vaccine development is desirable.
  • Common law qualification preferred.
  • Strong legal technical skills with a proven track record in drafting and negotiating agreements within cross-functional teams.
  • Sound knowledge of contract law, commercial law, and regulatory frameworks applicable to life sciences and public health.
  • Familiarity with intellectual property, antitrust, and trade sanctions is advantageous.
  • Experience working with business development teams is highly desirable.
  • Understanding of R&D, manufacturing, supply chain, or commercialization in pharma/vaccine sectors or access to medicines is strongly preferred.
  • Experience in international environments and working within cross-functional, multi-jurisdictional teams.
  • Excellent written and verbal communication skills in English; additional languages such as Norwegian, Arabic, Hindi, Chinese, French, German, Spanish, Portuguese are a plus.
  • Strong engagement and outcome-driven approach.
  • Confident communicator capable of influencing at all organizational levels.
  • Commitment to knowledge sharing and continuous learning.
  • Ability to take ownership and deliver solutions independently.
  • Resilient, self-motivated, quick learner able to work autonomously.
  • Effective time management and ability to handle competing priorities in a fast-paced environment.
  • Curiosity and enthusiasm for new ideas and approaches.
  • Ability to diplomatically challenge and commit to agreed paths forward.

Location and Travel

  • Position based in the UK, US, or Norway.
  • May require working across time zones corresponding to offices in London, Oslo, and Washington DC.
  • Infrequent travel to these locations or other countries as needed.

Compensation and Benefits

  • Opportunity to work with leading experts on global health challenges.
  • Experience contributing to international vaccine development efforts against emerging infectious diseases.
  • Diverse and inclusive working environment.

Application Details

  • Applications are reviewed on a rolling basis; early submission is advised.
  • Deadline for applications: 28th June 2026 at 23:59 CET.
  • Background verification will be conducted.

(Note: Contact details and application URLs have been removed.)